/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Unicycive Therapeutics Inc Share Price Today: Live Updates & Key Insights

Unicycive Therapeutics Inc share price today is $6.9308, up -1.17%. The stock opened at $6.795 against the previous close of $6.81, with an intraday high of $6.91 and low of $6.63.

Unicycive Therapeutics Inc Share Price Chart

style
pb-0

Unicycive Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Unicycive Therapeutics Inc Share Price Performance

$6.9308 -0.0117(-1.17%) UNCY at 23 Mar 2026 03:39 PM Biotechnology
Lowest Today 6.63
Highest Today 6.91
Today’s Open 6.795
Prev. Close 6.81
52 Week High 11.00
52 Week Low 3.71
Day’s Range: Low 6.63 High 6.91
52-Week Range: Low 3.71 High 11.00
1 day return -
1 Week return -4.06
1 month return +2.74
3 month return +15.23
6 month return +69.3
1 year return +957.01
3 year return +199.11
5 year return +16.43
10 year return -

Unicycive Therapeutics Inc Institutional Holdings

Vivo Capital, LLC 14.84

Millennium Management LLC 8.41

Octagon Capital Advisors LP 8.29

Nantahala Capital Management, LLC 7.79

Great Point Partners LLC 6.60

Vanguard Group Inc 6.54

Vanguard Total Stock Mkt Idx Inv 4.24

Logos Global Management LP 3.93

Citadel Advisors Llc 2.14

CANTOR FITZGERALD, L. P. 1.66

Vanguard Institutional Extnd Mkt Idx Tr 1.60

Geode Capital Management, LLC 1.42

BNP Paribas Arbitrage, SA 0.83

Dauntless Investment Group, LLC 0.74

Fidelity Extended Market Index 0.72

Omers Administration Corp 0.65

Longwood Capital Partners LLC 0.50

Squarepoint Ops LLC 0.46

State Street Corp 0.45

The Goldman Sachs Group Inc 0.37

Quadrature Capital Limited 0.32

XTX Topco Ltd 0.31

BlackRock Inc 0.30

Blackrock Extended Mkt Fund CF 0.29

Extended Equity Market Fund K 0.25

Fidelity Total Market Index 0.22

Fidelity Series Total Market Index 0.18

Spartan Extended Market Index Pool F 0.17

NT Ext Equity Mkt Idx Fd - L 0.16

Dimensional US Small Cap ETF 0.15

Vanguard Instl Ttl Stck Mkt Idx Tr 0.14

NT Ext Equity Mkt Idx Fd - NL 0.13

Northern Trust Extended Eq Market Idx 0.11

Spartan Total Market Index Pool G 0.10

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.10

Vanguard Balanced Index Inv 0.09

Dimensional US Core Equity 2 ETF 0.07

Vanguard U.S. Eq Idx £ Acc 0.07

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.06

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.06

Unicycive Therapeutics Inc Market Status

Strong Buy: 4

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Unicycive Therapeutics Inc Fundamentals

Market Cap 144.64 M

PB Ratio 3.859

PE Ratio 0.0

Enterprise Value 102.45 M

Total Assets 31.67 M

Volume 458608

Unicycive Therapeutics Inc Company Financials

Annual Revenue FY23:675000 0.7M, FY22:951000 1.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:951000 1.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-28074000 -28.1M, FY22:-18064000 -18.1M, FY21:-10632000 -10.6M, FY20:-2508000 -2.5M, FY19:-2304000 -2.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-138000 -0.1M, Q1/2025:-135000 -0.1M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-6011000 -6.0M, Q2/2025:-6447000 -6.4M, Q1/2025:570000 0.6M, Q3/2024:-4096000 -4.1M, Q2/2024:3930000 3.9M

About Unicycive Therapeutics Inc & investment objective

Company Information Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.

Organisation Biotechnology

Employees 22

Industry Biotechnology

CEO Dr. Shalabh K. Gupta M.D., MPA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Unicycive Therapeutics Inc FAQs

What is the share price of Unicycive Therapeutics Inc today?

The current share price of Unicycive Therapeutics Inc is $6.9308.

Can I buy Unicycive Therapeutics Inc shares in India?

Yes, Indian investors can buy Unicycive Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Unicycive Therapeutics Inc shares in India?

You can easily invest in Unicycive Therapeutics Inc shares from India by:

Can I buy fractional shares of Unicycive Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Unicycive Therapeutics Inc?

Unicycive Therapeutics Inc has a market cap of $144.64 M.

In which sector does Unicycive Therapeutics Inc belong?

Unicycive Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Unicycive Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Unicycive Therapeutics Inc?

The PE ratio of Unicycive Therapeutics Inc is N/A and the PB ratio is 3.86.